Opyt primeneniya pramipeksola v lechenii bolezni Parkinsona
- Authors: Fedorova N.V1,2, Kulua T.K1,2
-
Affiliations:
- ГОУ ДПО РМАПО Росздрава
- Центр экстрапирамидных заболеваний Минздравсоцразвития
- Issue: Vol 9, No 2 (2007)
- Pages: 103-107
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/92395
- ID: 92395
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N. V Fedorova
ГОУ ДПО РМАПО Росздрава; Центр экстрапирамидных заболеваний МинздравсоцразвитияКафедра неврологии
T. K Kulua
ГОУ ДПО РМАПО Росздрава; Центр экстрапирамидных заболеваний МинздравсоцразвитияКафедра неврологии
References
- Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол. журн. 1999; 6 (4): 45-9.
- Федорова Н.В., Шток В.Н. Стратегия и тактика лечения болезни Паркинсона. Консилиум. 2001; 3 (5): 237-42.
- Corrigan M.H, Denahan A.Q, Wright C.E, Ragual R.J. Comparison of pramipexole, fluoxetini, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
- Goetz C.G. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990; 40 (Suppl. 3): 50-4.
- Hubble J.P, Koller W.C, Cutler N.R et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18 (4): 338-47.
- Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double - blind, placebo - controlled, parallel - group study. Neurology 1997; 49 (1): 162-8.
- Molho E.S, Factor S.A, Weiner W.J et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995; (Suppl) V. 45: 225-30.
- Olanow C.W. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992; 19: 108-12.
- Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson's disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000; 23 (1): 34-44.
- Pinter M.M, Pogarell O, Oertel W.H. Efficasy, safety and tolerance of non - ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double - blind, placebo controlled, randomized, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66 (4): 436-41.
- Pogarell O, Gasser T, van Hilten J.J et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized double - blind, placebo controlled, multicentre study. J Neurol Neurosurg Psychiatry 2002; 72 (6): 713-20.
- Reichmann H, Brecht H.M, Kraus P.H et al. Pramipexole in Parkinson's disease. Results of a teraetment observation. Nervenarzt 2002; 73 (8): 745-50.
- Shannon K.M, Bennett J.P.Jr, Friedman J.H. Efficasy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49 (3): 724-8.
- The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000; 284 (15): 1931-8.
- The Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose - ranging study. JAMA 1997; 278 (2): 125-30.
- Wolters E.C, Tissingh G, Bergmans P.L.M et al. Dopamine agonists in Parkinson's disease. Neurology 1995; 45 (Suppl. 3): 28-34.
- Zenzola A, Diroma C, Fraddosio A et al. Efficacy and Tolerability of Dopamine Agonists in A Parkinsonian Population. Department of Neurological, University of Bari, Bari, Italy - 2000.
- Ziegler M, Rondor P. Activity of piribedil in Parkinson's disease: a multicenter study. Presse Med 1999; 28: 1414-8.
Supplementary files
